Antihypertensive Management Post-Endovascular AAA Repair

Primary Recommendation: Beta-Blockers First

The American College of Cardiology recommends beta-blockers as the first-line antihypertensive agent in patients following endovascular AAA repair, with the addition of ACE inhibitors or ARBs as second-line agents for blood pressure control and cardiovascular risk reduction 1, 2
Beta-blockers are the preferred initial antihypertensive because they uniquely reduce both blood pressure and the force of left ventricular ejection, directly decreasing mechanical stress on the aortic wall—a critical consideration in patients with aortic pathology 3

In patients undergoing AAA repair, metoprolol significantly reduced perioperative myocardial infarction and cardiac arrhythmias compared to no beta-blockade, with a reduction in myocardial infarction from 18% to 3% (p<0.05) and cardiac arrhythmias from 56.9% to 12.5% (p<0.001) 1, 2
Observational data from vascular surgery patients demonstrated that beta-blocker use was associated with a 50% reduction in perioperative myocardial infarction (p=0.03) 1, 2

The European Society of Cardiology recommends starting oral metoprolol or bisoprolol as the initial agent, titrating to achieve a heart rate ≤60 beats per minute and systolic blood pressure <120 mmHg 4, 3
For acute blood pressure control in the immediate postoperative period, intravenous beta-blockers, preferably esmolol, should be used due to its short half-life allowing rapid titration 3
The American Heart Association recommends continuing beta-blocker therapy indefinitely post-procedure as part of long-term cardiovascular risk management 1, 2

The American College of Cardiology recommends adding an ACE inhibitor or ARB as second-line agents if blood pressure remains uncontrolled on beta-blockers alone, as these agents provide additional cardiovascular protection and may slow aortic disease progression 5, 6
In Japanese patients with cardiovascular disease, valsartan reduced the composite cardiovascular outcome and specifically reduced aortic dissection risk (OR 0.18, 95% CI 0.04-0.88) 5

The American Heart Association recommends antiplatelet therapy with aspirin 81-325 mg daily to be continued indefinitely post-EVAR 7
The European Society of Cardiology recommends high-intensity statin therapy targeting LDL-C <55 mg/dL with ≥50% reduction from baseline for all patients with peripheral vascular disease, including AAA 6

The European Society of Cardiology recommends maintaining systolic blood pressure <120 mmHg and heart rate ≤60 beats per minute in the acute postoperative period 4, 3
For long-term management, stringent blood pressure control should be maintained, though specific targets should account for cerebral and renal perfusion, particularly in elderly patients, with a recommended systolic blood pressure target of <120 mmHg 5, 4

The American Heart Association recommends valsartan as the ARB with the strongest evidence in cardiovascular disease patients, reducing composite cardiovascular outcomes and specifically reducing aortic dissection risk (OR 0.18, 95% CI 0.04-0.88) 8
The American College of Cardiology suggests that losartan or irbesartan may be beneficial in reducing aortic root enlargement rates in patients with Marfan syndrome with severe aortic root enlargement 8

The use of ACE inhibitors, such as those used in conjunction with ARBs, has been associated with a reduced risk of AAA rupture (OR 0.87, 95% CI 0.81-0.93; p<0.001), although ARBs themselves did not demonstrate this benefit 8